A case of delayed malposition of a CoreValve device causing obstruction of coronary ostia is described. Nine months after the original implant, the patient developed an acute coronary syndrome and was readmitted to hospital. Angiogram demonstrated an ostial stenosis of both the left main stem and the right coronary ostia, which were filled by a paravalvular leakage of the bioprosthesis. Gated computed tomography scan with 3D reconstruction showed valve malposition with cusps situated 14 mm above the ostium of the right coronary and the presence of fibrous and calcific agglomerations associated to one of the cusp causing a tight stenosis of the left ostium. Computed tomography scan is a crucial imaging technique in the transcatheter aortic valve replacement field and in this case enabled us to identify an interesting phenomenon of fibrosis/calcification originating at the level of the misplaced valve, which was actually the triggering cause of the coronary obstruction. Considering the reported need for more accurate investigations regarding the predictors of negative outcomes and the selection of transcatheter aortic valve replacement candidates, the use of cardiac-gated computed tomography should be stimulated and promoted as a valuable aid for the diagnosis and further clinical decision making in those patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ejcts/ezx266 | DOI Listing |
Eur Heart J Case Rep
January 2025
Department of Cardiovascular Medicine, Sendai Kousei Hospital, 1-20 Tsutsumidori-amamiya, Aoba Ward, Sendai, Miyagi 9810914, Japan.
Background: Transcatheter edge-to-edge mitral valve repair (M-TEER) using the MitraClip system is primarily performed using the transfemoral approach. However, when this approach is not feasible, the transjugular approach can be used as an alternative.
Case Summary: A 57-year-old man presented with heart failure and persistent New York Heart Association class IV symptoms, refractory to guideline-directed medical therapy, intravenous therapy, and intra-aortic balloon pumping.
Catheter Cardiovasc Interv
January 2025
Department of Cardiology, Turku University Hospital, Turku, Finland.
Background: Vascular and bleeding complications remain a concern after transfemoral transcatheter aortic valve replacement (TAVR). The impact of the sheath type on these complications remains unclear.
Methods: The prospective MARVEL registry study analyzed enrolled 500 patients undergoing large-bore transfemoral procedures and arteriotomy closure with the MANTA vascular closure device from 10 hospitals in Europe and Canada.
Catheter Cardiovasc Interv
January 2025
Division of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.
Background: The co-existence of severe aortic stenosis (AS) and hypertrophic cardiomyopathy (HCM) is not uncommon. Surgical intervention is the gold standard management. Patients with high surgical risk might undergo transcatheter aortic valve replacement (TAVR).
View Article and Find Full Text PDFCatheter Cardiovasc Interv
January 2025
Department of Cardiology, Reims University Hospital, Reims, France.
Aortic annular rupture is a rare and usually fatal complication of TAVR. We report the case of a sub-annular aortic rupture contained in the right ventricle and percutaneously repaired. The procedure was complicated by new-onset severe tricuspid regurgitation related to tricuspid injury during wire externalization and immediately treated by transcatheter edge-to-edge repair.
View Article and Find Full Text PDFA A Pract
January 2025
Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas.
Transcatheter aortic valve replacement (TAVR) is a common treatment for severe aortic stenosis (AS), but it carries the risk of severe complications, including device embolization. We present a case of a TAVR valve embolization into the left ventricular outflow tract (LVOT), diagnosed with transesophageal echocardiography (TEE) shortly after device deployment. The dislodged valve was successfully retrieved from the LVOT into the aorta, flattened, and stabilized with a thoracic endovascular aneurysm repair (TEVAR) stent, enabling the successful implantation of a new TAVR valve.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!